NASDAQ:MRVI Maravai LifeSciences - MRVI Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $14.48 -0.40 (-2.69%) (As of 02/6/2023 12:00 AM ET) Add Compare Share Share Today's Range$14.44▼$14.8350-Day Range$12.50▼$15.5052-Week Range$12.16▼$41.82Volume1.33 million shsAverage Volume1.44 million shsMarket Capitalization$3.70 billionP/E Ratio8.09Dividend YieldN/APrice Target$23.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Maravai LifeSciences MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside58.8% Upside$23.00 Price TargetShort InterestHealthy4.73% of Float Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment0.84Based on 4 Articles This WeekInsider TradingN/AProj. Earnings Growth-81.01%From $1.79 to $0.34 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.46 out of 5 starsMedical Sector151st out of 1,027 stocksPharmaceutical Preparations Industry62nd out of 500 stocks 3.4 Analyst's Opinion Consensus RatingMaravai LifeSciences has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.00, Maravai LifeSciences has a forecasted upside of 58.8% from its current price of $14.48.Amount of Analyst CoverageMaravai LifeSciences has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.73% of the float of Maravai LifeSciences has been sold short.Short Interest Ratio / Days to CoverMaravai LifeSciences has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Maravai LifeSciences has recently decreased by 3.75%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMaravai LifeSciences does not currently pay a dividend.Dividend GrowthMaravai LifeSciences does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMaravai LifeSciences has received a 67.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Deoxyribonucleic acid (DNA)", "Microbiology laboratory services for research", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Maravai LifeSciences is -1.23. Previous Next 2.7 News and Social Media Coverage News SentimentMaravai LifeSciences has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Maravai LifeSciences this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for MRVI on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Maravai LifeSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Maravai LifeSciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.11% of the stock of Maravai LifeSciences is held by insiders.Percentage Held by Institutions48.67% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Maravai LifeSciences are expected to decrease by -81.01% in the coming year, from $1.79 to $0.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Maravai LifeSciences is 8.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.06.Price to Earnings Ratio vs. SectorThe P/E ratio of Maravai LifeSciences is 8.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 121.36.Price to Book Value per Share RatioMaravai LifeSciences has a P/B Ratio of 6.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Maravai LifeSciences (NASDAQ:MRVI) StockMaravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.Read More Receive MRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address MRVI Stock News HeadlinesFebruary 6, 2023 | finance.yahoo.comAre Strong Financial Prospects The Force That Is Driving The Momentum In Maravai LifeSciences Holdings, Inc.'s NASDAQ:MRVI) Stock?February 2, 2023 | morningstar.comMaravai LifeSciences Holdings Inc Ordinary Shares - Class A MRVI Stock QuoteFebruary 6, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...February 1, 2023 | finance.yahoo.comMaravai LifeSciences to Host Earnings Conference Call on Wednesday, February 22, 2023January 16, 2023 | finance.yahoo.com3 Biopharma Stocks That Could Help Make You a FortuneJanuary 6, 2023 | seekingalpha.comMaravai LifeSciences: Remaining Constructive, But Further Evidence NeededJanuary 5, 2023 | msn.comMaravai LifeSciences downgraded to neutral at UBS on lack of near-term catalystJanuary 5, 2023 | seekingalpha.comMaravai LifeSciences Holdings: A Tough Year Or Two AheadFebruary 6, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...December 7, 2022 | msn.com6 Analysts Have This to Say About Maravai LifeSciencesDecember 2, 2022 | seekingalpha.comMaravai LifeSciences appoints intemin CEODecember 1, 2022 | finance.yahoo.comMaravai LifeSciences Announces Updated CEO Leadership Transition PlansNovember 16, 2022 | finance.yahoo.comMaravai LifeSciences Named to the 2022 Deloitte Technology Fast 500™ List of Fastest-Growing Companies in North AmericaNovember 11, 2022 | 247wallst.comSelect Equity Makes Large Cut to Maravai LifeSciences (MRVI) PositionNovember 9, 2022 | finance.yahoo.comMaravai LifeSciences Holdings Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 7, 2022 | finance.yahoo.comNew Kit Predicts Retroviral Particle Clearance in Biopharmaceutical ManufacturingNovember 6, 2022 | finance.yahoo.comThings Look Grim For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) After Today's DowngradeNovember 4, 2022 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About Maravai LifeSciencesNovember 4, 2022 | markets.businessinsider.comWhere Maravai LifeSciences Stands With AnalystsNovember 4, 2022 | markets.businessinsider.comAnalyst Ratings for Maravai LifeSciencesNovember 4, 2022 | finance.yahoo.comMaravai LifeSciences Announces November and December 2022 Investor Conference ScheduleNovember 3, 2022 | seekingalpha.comMaravai slumps 13% on slashed FY22 revenue outlook, Q3 earnings fallNovember 2, 2022 | finance.yahoo.comMaravai LifeSciences Reports Third Quarter 2022 Financial ResultsOctober 29, 2022 | finance.yahoo.comThis Fallen Growth Stock Is Still a Wall Street Favorite: Here's WhyOctober 24, 2022 | finance.yahoo.comThis Pandemic Star Is Embroiled in CEO DramaOctober 22, 2022 | seekingalpha.comMaravai LifeSciences: Establishing The DiagnosisOctober 19, 2022 | seekingalpha.comMaravai Lifesciences temporarily reinstates Carl Hull as CEOSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address MRVI Company Calendar Last Earnings11/10/2021Today2/06/2023Next Earnings (Confirmed)2/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRVI CUSIPN/A CIK1823239 Webwww.maravai.com Phone858-546-0004FaxN/AEmployees470Year FoundedN/APrice Target and Rating Average Stock Price Forecast$23.00 High Stock Price Forecast$32.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside+58.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$1.79 Trailing P/E Ratio8.09 Forward P/E Ratio8.09 P/E GrowthN/ANet Income$182.04 million Net Margins26.29% Pretax Margin66.20% Return on Equity69.19% Return on Assets23.24% Debt Debt-to-Equity Ratio0.62 Current Ratio7.22 Quick Ratio6.68 Sales & Book Value Annual Sales$906.73 million Price / Sales4.08 Cash Flow$1.68 per share Price / Cash Flow8.64 Book Value$2.14 per share Price / Book6.77Miscellaneous Outstanding Shares255,207,000Free Float254,926,000Market Cap$3.70 billion OptionableNot Optionable Beta-0.22 Key ExecutivesMr. Carl W. Hull (Age 64)Co-Founder and Exec. Chairman & Interim CEO Comp: $1.78MMr. Kevin M. Herde (Age 51)Exec. VP & CFO Comp: $841.6kMr. Kurt Oreshack (Age 42)Exec. VP, Gen. Counsel & Sec. Comp: $701.4kMs. Christine Dolan (Age 55)Chief Operating Officer of Biologics Safety Testing Comp: $844.67kMr. Brian Neel (Age 47)Chief Operating Officer of Nucleic Acid Production Comp: $797.38kDr. Peter Michael Leddy Ph.D. (Age 60)Exec. VP & Chief Admin. Officer Ms. Debra HartSr. Director of Investor RelationsMs. Doreen PippenVP of MarketingMr. William Martin IIIPres of Biologics Safety TestingMore ExecutivesKey CompetitorsArrowhead PharmaceuticalsNASDAQ:ARWRAmicus TherapeuticsNASDAQ:FOLDCytokineticsNASDAQ:CYTKZai LabNASDAQ:ZLABPTC TherapeuticsNASDAQ:PTCTView All CompetitorsInsiders & InstitutionsPacer Advisors Inc.Bought 991,860 shares on 2/6/2023Ownership: 0.647%Brinker Capital Investments LLCBought 15,069 shares on 2/6/2023Ownership: 0.006%Los Angeles Capital Management LLCBought 12,219 shares on 2/6/2023Ownership: 0.005%Curi Wealth Management LLCBought 478,636 shares on 2/3/2023Ownership: 0.361%Simplex Trading LLCBought 100 shares on 2/2/2023Ownership: 0.000%View All Institutional Transactions MRVI Stock - Frequently Asked Questions Should I buy or sell Maravai LifeSciences stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRVI shares. View MRVI analyst ratings or view top-rated stocks. What is Maravai LifeSciences' stock price forecast for 2023? 8 equities research analysts have issued 12-month price objectives for Maravai LifeSciences' shares. Their MRVI share price forecasts range from $16.00 to $32.00. On average, they predict the company's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 56.4% from the stock's current price. View analysts price targets for MRVI or view top-rated stocks among Wall Street analysts. How have MRVI shares performed in 2023? Maravai LifeSciences' stock was trading at $14.31 on January 1st, 2023. Since then, MRVI shares have increased by 2.8% and is now trading at $14.71. View the best growth stocks for 2023 here. When is Maravai LifeSciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023. View our MRVI earnings forecast. How can I listen to Maravai LifeSciences' earnings call? Maravai LifeSciences will be holding an earnings conference call on Wednesday, February 22nd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link. How were Maravai LifeSciences' earnings last quarter? Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) issued its quarterly earnings results on Wednesday, November, 10th. The company reported $0.44 earnings per share for the quarter, beating analysts' consensus estimates of $0.35 by $0.09. The firm earned $204.81 million during the quarter, compared to the consensus estimate of $199.68 million. Maravai LifeSciences had a trailing twelve-month return on equity of 69.19% and a net margin of 26.29%. What guidance has Maravai LifeSciences issued on next quarter's earnings? Maravai LifeSciences issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of $1.76-$1.80 for the period, compared to the consensus estimate of $1.76. The company issued revenue guidance of $880.00 million-$890.00 million, compared to the consensus revenue estimate of $889.97 million. When did Maravai LifeSciences IPO? (MRVI) raised $1.3 billion in an initial public offering (IPO) on Friday, November 20th 2020. The company issued 50,000,000 shares at a price of $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs served as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers. What is Maravai LifeSciences' stock symbol? Maravai LifeSciences trades on the NASDAQ under the ticker symbol "MRVI." Who are Maravai LifeSciences' major shareholders? Maravai LifeSciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vaughan Nelson Investment Management L.P. (0.49%), Curi Wealth Management LLC (0.36%), Natixis Advisors L.P. (0.18%), State of Alaska Department of Revenue (0.15%), Bank Julius Baer & Co. Ltd Zurich (0.09%) and New York State Common Retirement Fund (0.06%). How do I buy shares of Maravai LifeSciences? Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Maravai LifeSciences' stock price today? One share of MRVI stock can currently be purchased for approximately $14.71. How much money does Maravai LifeSciences make? Maravai LifeSciences (NASDAQ:MRVI) has a market capitalization of $3.75 billion and generates $906.73 million in revenue each year. The company earns $182.04 million in net income (profit) each year or $1.79 on an earnings per share basis. How many employees does Maravai LifeSciences have? The company employs 470 workers across the globe. How can I contact Maravai LifeSciences? Maravai LifeSciences' mailing address is 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.maravai.com. The company can be reached via phone at 858-546-0004 or via email at ir@maravai.com. This page (NASDAQ:MRVI) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.